diaDexus, Inc. announced the appointment of James Sulat and Elizabeth Hutt as members of its board of directors effective immediately. Mr. Sulat will serve as chairman of the audit committee and will serve on the nominating and corporate governance committee. Ms. Hutt will serve on the audit and compensation committees.

The company also announced the resignations of Andrew Galligan, James Panek, and Charles Patrick from its Board of Directors. James Sulat currently serves as chairman of the board of directors of Momenta Pharmaceuticals, Inc., as vice chairman of the supervisory board of Valneva SE, and as a member of the board of directors of AMAG Pharmaceuticals, Inc. Previously, Mr. Sulat served as the chief executive officer, chief financial officer and a member of the board of directors of Maxygen, Inc. Elizabeth Hutt is a member of the board of directors and the chief executive officer of NuGEN Technologies, Inc. Ms. Hutt joined NuGEN in 2004 as vice president commercial, responsible for establishing the company's brand, portfolio strategy and global sales and technical support infrastructure.